Scientists Discover Weakness in Deadly Pancreatic Cancer with Experimental Drug

An experimental drug, daraxonrasib, targeting the KRAS protein, has reportedly doubled the survival rate for pancreatic cancer patients, offering new hope for the previously fatal disease.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

index-hrSerbian98d ago

Kako su znanstvenici pronašli slabost jednog od najsmrtonosnijih karcinoma

EKSPERIMENTALNA tableta daraxonrasib, koja cilja na KRAS protein, udvostručila je preživljenje pacijenata s rakom gušterače, nudeći novu nadu u liječenju dosad smrtonosne bolesti.

Read full article →

Scientists Discover Weakness in Deadly Pancreatic Cancer with Experimental Drug

Sources

Kako su znanstvenici pronašli slabost jednog od najsmrtonosnijih karcinoma

Related Stories

Lionel Richie Hospitalized in ICU After Collapsing During St. Louis Concert

Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue

Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases

England Pharmacies to Offer Free Quick Cholesterol Screening Tests